• News

Scout Bio Expands Gene Therapy Collaboration with the University of Pennsylvania Via Next-Generation Vector Technologies

December 7, 2021

Partnership agreement includes exclusive rights in animal health to novel viral vector capsid and expands additional option rights to novel capsids Next-generation novel adeno-associated viral (AAV) vector capsid promises…

  • News

Scout Bio Named Best New Start-Up for 2021

November 8, 2021

IHS Markit recognizes Scout Bio for pioneering therapies in companion animal medicine PHILADELPHIA, November 08, 2021 — Scout Bio, a biotechnology company focused on one-time AAV gene therapies for…

  • News

Scout Bio Initiates Multi-Center Clinical Study of Gene Therapy for Chronic Arthritis Pain In Cats

October 28, 2021

– First vectorized antibody gene therapy to be studied in pets – Strong initial in-species data support therapeutic profile of one-time gene therapy designed for long-term pain management –…

  • News

Scout Bio Closes $33 Million Series B2 Financing to Advance its Portfolio of Single Injection Gene Therapy Technology for the Treatment of Chronic Diseases in Pets

October 19, 2021

– Proceeds to support advancing single injection Adeno-Associated Viral (AAV) vector therapeutics targeting chronic companion animal diseases including diabetes, pain, and anemia associated with chronic kidney disease (CKD) – New…

  • News

Scout Bio to Present at Upcoming October Investor Conferences

October 4, 2021

PHILADELPHIA, Oct. 04, 2021 (GLOBE NEWSWIRE) — Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic…

  • News

Scout Bio Successfully Completes Pilot Clinical Study of SB-001, A Single-Injection AAV Gene Therapy for the Treatment of Feline CKD-Associated Anemia

September 9, 2021

PHILADELPHIA, September 9, 2021 — Scout Bio today announced the successful completion of a CKD-associated anemia study in client owned cats treated with SB-001, an AAV expressing feline erythropoietin (fEPO).…

  • News

Scout Bio to Present at Stifel 2021 Virtual Jaws & Paws Conference

May 27, 2021

PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) — Scout Bio today announced that Mark Heffernan, Chief Executive Officer, will present at the upcoming Stifel 2021 Virtual Jaws & Paws Conference…

  • News

Scout Bio to Present at the BofA Securities 2021 Animal Health Summit

February 19, 2021

PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) – Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions,…

  • News

Scout Bio Advances Novel Gene Therapy for the Treatment of Feline Diabetes

October 28, 2020

Two pilot studies initiated to explore clinical applications for this convenient, one-time injectable treatment Positions Scout Bio as the first company to advance novel GLP-1 constructs for gene therapy…

  • News

Scout Bio Reports Statistically Significant Clinical Outcomes for Pilot Study of SB-001 for Treatment of CKD-Associated Anemia in Felines

September 30, 2020

SB-001, a gene therapy expressing feline erythropoietin (fEPO), demonstrates clinically relevant hematocrit improvements in end-stage anemia patients and improved quality of life scores PHILADELPHIA, Sept. 30, 2020 (GLOBE NEWSWIRE)…